Compare BRCB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | DMAC |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.5M | 457.2M |
| IPO Year | 2025 | N/A |
| Metric | BRCB | DMAC |
|---|---|---|
| Price | $24.33 | $9.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $28.40 | $15.50 |
| AVG Volume (30 Days) | 361.2K | ★ 575.5K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $189,494,000.00 | N/A |
| Revenue This Year | $26.92 | N/A |
| Revenue Next Year | $27.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.30 | N/A |
| 52 Week Low | $19.32 | $3.19 |
| 52 Week High | $30.40 | $10.42 |
| Indicator | BRCB | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 71.27 |
| Support Level | N/A | $7.76 |
| Resistance Level | N/A | $10.42 |
| Average True Range (ATR) | 0.00 | 0.69 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 0.00 | 76.95 |
Black Rock Coffee Bar Inc is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. It offers a broad range of premium coffee beverages, from its deliciously refreshing Nitro Cold Brew to its unapologetically indulgent Caramel Blondie. The company also offer competitively priced, premium classics, including the Americano and customizable Lattes, providing a high perceived value offering to its guests.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.